Bharat Tewarie, Chief Executive Officer at Helio Genomics and Founder of Boston BioPharma Consultants, shared a post on LinkedIn:
“Today our landmark CLiMB study evaluating HelioLiver, our multi-analyte blood-based test for early liver cancer detection, has been published in the Journal of Hepatology.
This marks a major milestone after years of dedicated work. More importantly, it addresses a critical gap in today’s standard of care.
Hepatocellular carcinoma (HCC) remains one of the most lethal cancers because it is so often diagnosed too late. The current surveillance standard, ultrasound, frequently misses tumors in their earliest, most treatable stages.
The CLiMB study, the largest prospective, multicenter U.S. trial of its kind, provides the first head-to-head data demonstrating that HelioLiver can detect liver cancer at these early stages.
“For patients, this is transformative. Instead of facing limited options in advanced disease, they now have a reliable, simple blood-based tool that gives them a real fighting chance.”
For patients, this is transformative. Earlier detection means more high-risk individuals with cirrhosis can access life-extending and potentially curative therapies, dramatically improving survival rates and quality of life. Instead of facing limited options in advanced disease, they now have a reliable, simple blood-based tool that gives them a real fighting chance.
We are proud to share these results with the medical community and deeply grateful to the nearly 2,000 patients and clinical investigators across the country whose participation made this study possible.
This is just the beginning. At Helio Genomics, we remain committed to advancing precision oncology so that fewer patients ever hear the words ‘too late.’”
The Study
Landmark CLiMB Study Demonstrates Superior Sensitivity of HelioLiver, a Multi-Analyte Blood Test, Over Ultrasound for Early Detection of Hepatocellular Carcinoma. Read the article.
View source version on oncodaily.com.